ArticleJACC. Asia2022
Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation.
Article in JACC. Asia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II.Journal of the American Heart Association · 2023Trial
- Real-world evidence on off-label underdosing of direct oral anticoagulants in Asian patients with atrial fibrillation: prescribing patterns, determinants, and outcomes.Future science OA · 2026Article
- Which kidney function estimate should guide anticoagulant dosing and risk assessment in atrial fibrillation?European heart journal open · 2026Article
- Cardiovascular-kidney-metabolic interplay in patients with atrial fibrillation receiving direct oral anticoagulants.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use Comparison.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies.Clinical pharmacology and therapeutics · 2025Article
- Impact of Renal Function Estimation Formulae on Use and Correct Dosing of NOACs in Patients with Non-valvular Atrial Fibrillation in Real Life in Germany.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Article
- Challenges in renally eliminated medication use: Evaluating cystatin C and serum creatinine eGFR discordance.Pharmacotherapy · 2024Article
- Article
- Observational
- A real-world exploration into clinical outcomes of direct oral anticoagulant therapy in people with chronic kidney disease: a large hospital-based study.Journal of nephrology · 2024Article
- Renal function assessment in older people: comparative analysis of estimation equation with serum creatinine.Frontiers in medicine · 2024Article
- DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023Observational
- Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation.Clinical kidney journal · 2023Article
- Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: An Asian Perspective.JACC. Asia · 2023Review
- From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors.International journal of molecular sciences · 2022Article
- Stroke Prevention in Atrial Fibrillation: A Scientific Statement ofJACC. Asia · 2022Review
- Which Renal Function Equation Should Be Used for Prescribing DOACs in Patients With Atrial Fibrillation?JACC. Asia · 2022Article
- Clinical Associations with the differences in rivaroxaban dosing in patients with atrial fibrillation stratified by three renal function formulae.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Randomized trials of direct oral anticoagulants (DOACs) adopted the Cockcroft-Gault (CG) formula to calculate estimated glomerular filtration rate (eGFR) to determine the dosages of DOACs. Objectives: The authors aimed to investigate the agreements/disagreements of eGFRs calculated using different equations (CG, Modified Diet in Renal Disease [MDRD], and Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formulas), and their impacts on the dosages of DOACs and clinical outcomes. Methods: Medical data from a multicenter health care provider in Taiwan including 39,239 patients with atrial fibrillation were used. Among these patients, there were 11,185 and 2,323 patients treated with DOACs and warfarin, respectively. Results: At the cutoff values of eGFR of <15, 15-50, and >50 mL/min, the agreements were 78% between MDRD and CG and 81% between CKD-EPI and CG. The disagreements among the different equations were largely due to overestimations, especially for patients aged >75 years and with a body weight of <50 kg (58.8% for MDRD and 50.9% for CKD-EPI). Among patients receiving DOACs whose dosages were defined as "on label" based on MDRD or CKD-EPI, only those whose dosages were "truly on label" based on CG were associated with a lower risk of major bleeding (adjusted HR: 0.34; 95% CI: 0.26-0.45) compared to warfarin. Conclusions: The adoptions of MDRD or CKD-EPI rather than CG would result in inappropriate dosing of DOACs (mainly overdosing), which would attenuate the advantages of DOACs compared to warfarin. The CG equation should be used as the gold standard to calculate eGFRs and guide the DOAC dosages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.